...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of stroke and cerebrovascular diseases: The official journal of National Stroke Association >Safety and Feasibility of Carotid Artery Stenting with Dual-Echo Technique to Minimize Iodinated Contrast Dose
【24h】

Safety and Feasibility of Carotid Artery Stenting with Dual-Echo Technique to Minimize Iodinated Contrast Dose

机译：双回波技术颈动脉支架的安全性和可行性最小化碘化对比剂量

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The aim of this study was to evaluate the safety and feasibility of carotid artery stenting (CAS) employing dual-ultrasound technique and administering a minimal contrast agent in patients with renal insufficiency. Methods: Between September 2009 and July 2013, 63 consecutive patients underwent CAS at our institution: dual-echo carotid artery stenting (DECAS) in 7 patients with renal insufficiency and standard carotid artery stenting (STCAS) in the remaining 56 patients. Periprocedural adverse events and outcomes were compared between the 2 groups. Results: Technical success was achieved in all cases. The 3 procedure-related complications were 1 case of transient hemiparesis in the DECAS group and 1 transient and 1 permanent case of hemiparesis in the STCAS group. The rate of positive diffusion-weighted-imaging lesions did not differ significantly between the 2 groups (28.6% versus 12.5%, P = .26). A significantly smaller volume of contrast was used in DECAS (15 versus 163 mL, P .01). The change in creatinine level remained stable after CAS and did not differ between the 2 groups (. 02 versus .03 mg/dL, P = .96). Conclusions: DECAS is safe and feasible for patients with preexisting renal insufficiency and can provide an alternative for patients with carotid stenosis and renal insufficiency.
机译：背景：本研究的目的是评估肾功能不全患者颈动脉支架置入术（CAS）的安全性和可行性，该术式采用双超声技术，并使用少量对比剂。方法：2009年9月至2013年7月，我们机构连续63例患者接受CAS治疗：7例肾功能不全患者接受双回声颈动脉支架（DECAS）治疗，其余56例患者接受标准颈动脉支架（STCAS）治疗。比较两组围手术期不良事件和结果。结果：所有病例均获得技术成功。3例手术相关并发症为DECAS组1例暂时性偏瘫，STCAS组1例暂时性和永久性偏瘫。两组间扩散加权成像阳性病变的发生率无显著差异（28.6%对12.5%，P=0.26）。十次扫描中使用的对比剂体积明显较小（15毫升对163毫升，P；01）。CAS后肌酐水平的变化保持稳定，两组之间没有差异（0.02和0.03 mg/dL，P=0.96）。结论：DECAS治疗原发性肾功能不全患者安全可行，可为颈动脉狭窄和肾功能不全患者提供替代方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号